Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions and regulatory agencies across 62 countries.
Certara Announces New Versions of Biosimulation Software for Development of Novel Biologics
Jun 21, 2022
New capabilities enhance clinical predictability for different compounds across more therapeutic areas PRINCETON, N.J. , June 21, 2022 (GLOBE NEWSWIRE) -- Certara , a global leader in biosimulation, today announced the release of new versions of its Immunogenicity (IG), Immuno -oncology (IO) and
Certara Reports First Quarter 2022 Financial Results
May 05, 2022
PRINCETON, N.J. , May 05, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2022. First Quarter Highlights: Revenue was $81.6 million , compared to $66.7 million in the first quarter of
PRINCETON, N.J. , May 03, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences: Bank of America 2022 Healthcare Conference Date and Time: Tuesday, May 10 at 3:00 p.m.